April 28th 2025
New research suggests classical biomarkers cannot discriminate between refractory and non-refractory rheumatoid arthritis.
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Benefits of Excluding Aspirin From Antithrombotic Regimen in Patients With LVADs
November 15th 2023New research highlighted how aspirin is unnecessary in antithrombotic regimens for patients with advanced heart failure and fully magnetically levitated left ventricular assist devices (LVADs).
Read More
Study Identifies Predictors of Fibromyalgia, Chronic Fatigue in IBS Patients
November 14th 2023A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared with those without IBS.
Read More
Study Reveals Factors That Further Increase Colorectal Cancer Risk for Adults With T2D
November 14th 2023The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.
Read More
Therapists’ Perspectives on Access to Telemental Health Among Medicaid-Enrolled Youth
This qualitative study elucidates therapists’ perspectives on barriers to and facilitators of access to telemental health among Medicaid-enrolled youth served by a large safety-net organization.
Read More
Personalized Medicine Would Offer Great Benefits to Patients With PAH
November 10th 2023In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to expand personalized medicine.
Read More
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Read More
Rituximab Demonstrates Potential Efficacy in Treatment of Special Forms of RA
November 8th 2023A retrospective analysis suggested that administering rituximab to patients with rheumatoid arthritis complicated by lymphoma, systemic vasculitis, or extra-articular lesions was associated with improved outcomes.
Read More
A Comprehensive Approach to Fourth-Trimester Care Aims to Overcome Newborn Health Disparities
November 8th 2023Care in the fourth-trimester, when the birth has taken place and the mother and baby return home, is crucial for the well-being of the mother or the birthing person, Takiyah Durham, MBA, explains in an interview.
Watch
Myasthenia Gravis Potential Result of Cancer Treatment
November 8th 2023When patients are undergoing treatment for cancer, clinicians should be aware of the potential to develop myasthenia gravis from immune checkpoint inhibitors (ICI), new research stresses, with ongoing surveillance and risk factor identification becoming necessary steps.
Read More
Rhenium Obisbemeda for Breast Cancer, Leptomeningeal Metastases Receives ODD From FDA
November 6th 2023Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.
Read More
Rates of Elevated LDL-C Have Decreased, but Awareness, Treatment Still Suboptimal
November 6th 2023The prevalence of severely elevated low-density lipoprotein cholesterol (LDL-C) has declined in recent decades, but 1 in 17 US adults in a recent analysis had levels of LDL-C that would warrant consideration of pharmacotherapy, and 1 in 48 had high levels of LDL-C that are indicated for medication.
Read More
Multiple Barriers Impact Kidney Care Disparities in LGBTQ+ Individuals
November 5th 2023Presenters at American Society of Nephrology Kidney Week 2023 highlighted the importance of understanding the barriers faced by the LGBTQ+ community that impact kidney outcomes and the need to gather better data for studying these issues.
Read More
Prediction Model Effective for Community-Acquired Pneumonia in Those With Acute Asthma Exacerbations
November 4th 2023This newly developed prediction model evaluating community-acquired pneumonia risk was noted to demonstrate accuracy, strong discriminatory qualities, and practicability in clinical settings.
Read More